CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Echinochrome A +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05531019
NCT05531019N/ACompleted
CompareCT.gov

COVID-19 Sequelae: Treatment and Monitoring of Persistent Symptoms, a Decentralized Approach Focus on the Patient. Use of Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A.

Fernando Saldarini·interventional·Posted Sep 7, 2022·Updated Feb 28, 2023

In Brief

A clinical study evaluating Echinochrome A and Control for Long COVID. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The aim of this study is to assess the efficacy and efficiency of a nutraceutical from sea urchin eggs with Echinochrome A in the inflammation of tissues in subjects with long Corona Virus (COVID) syndome

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLong COVID
CountriesArgentina
CollaboratorsUniversidad Nacional de la Patagonia San Juan Bosco, Ministerio de Ciencia, Tecnologia e Innovación, Argentina, Hospital de Infecciosas Francisco Javier Muniz

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 7, 2022
Enrollment StartSep 22, 2021
Primary CompletionDec 8, 2022
Study CompletionDec 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.8 years ago

Interventions

Echinochrome Adietary

Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.

Controlother

Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment